Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;16(5):267-276.
doi: 10.1007/s10269-014-2391-1. Epub 2014 Dec 21.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)

J P Metges  1 , M A Lebot  2 , R Faroux  3 , F Riaud  3 , E Gamelin  4 , O Capitain  5 , V Guérin Meyer  5 , P Leynia  5 , J Y Douillard  6 , H Senellart  7 , S Rochard  7 , C Louvigné  7 , L Campion  7 , O Dupuis  8 , C Grollier  8 , N A Achour  9 , B Person  9 , J L Raoul  10 , E Boucher  10 , C Bertrand  10 , J F Ramée  11 , L Guivarch  11 , P L Etienne  12 , S Roussel  13 , H Desclos  14 , M N Julien  14 , M I Labarre  14 , V Klein  15 , R Bessard  16 , C Stampfli  17 , F Royet  17 , J Faycal  18 , S Gouva  18 , G Le Bihan  19 , M Couturier  19 , A Gourlaouen  20 , C Bertholom  20 , M Porneuf  21 , E Jobard  21 , E Peguet  21 , D Grasset  22 , J F Bouret  22 , V Bicheler  22 , A Ulvoas  22 , L Miglianico  23 , C Chouzenoux  23 , P Deguiral  24 , L Derenne  24 , D Martin  25 , P Michel Langlet  25 , C Bodin  25 , V Rossi  26 , S Barré  26 , O Cojocarasu  27 , C Naveau Ploux  27 , A M Vidal  28 , I Cumin  29 , J Egreteau  29 , A Brouard  29 , T Matysiak Budnik  30 , P Thomaré  30 , A S Le Bris Michel  31 , G Piriou  31 , R Largeau  31 , C Elhannani  32 , E Crespeau  32 , F Suberville  33 , H Bourgeois  34 , C Riche  34 , D Déniel Lagadec  34 , F Marhuenda  34 , F Grudé  34
Affiliations

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)

J P Metges et al. Oncologie (Paris). 2014.

Abstract
in English, French

Background: In 2006, bevacizumab, a targeted therapy agent was combined with FOLFIRI for the firstline treatment of patients with unresectable metastatic colorectal cancer.

Methods/results: A study on a homogenous series of 111 patients from the Brittany and Pays de la Loire areas who received bevacizumab-FOLFIRI as first-line treatment in 2006 showed the following results: 51 responses, 29 stabilisations, 21 progressions and 10 cases of toxicity prior to assessment. Median overall survival (OS) was 25.1 months and median progression-free survival was 10.2 months. Surgery secondary to treatment tripled median OS which reached 59.2 months in resected patients versus 18.8 months in unresected patients. Comparison of patients aged more or less than 70 years showed no differences in terms of benefits or risks.

Conclusion: Bevacizumab-FOLFIRI could be administered as part of a routine care protocol to elderly patients previously evaluated by a geriatric assessment and validated by a multidisciplinary staff.

En 2006, bevacizumab-FOLFIRI représente la thérapie ciblée administrable dès la première ligne chez les patients porteurs d’un cancer colorectal métastatique non opérable. Une série homogène de 111 patients colligés en région Bretagne et Pays de la Loire ayant reçu du bevacizumab- FOLFIRI en première ligne en 2006 révèle les résultats suivants: 51 réponses, 29 stabilités, 21 progressions et 10 toxicités avant évaluation. La médiane de survie globale (OS) est de 25,1 mois et la médiane de survie sans progression (PFS) de 10,2 mois. Dans le cas d’une chirurgie secondaire, l’OS médian triple de 18,8 mois chez les patients non réséqués versus 59,2 mois ceux réséqués. En comparant les sujets âgés de plus et de moins de 70 ans, aucune différence n’a été mise en évidence en termes de bénéfice ou de risque. Bevacizumab-FOLFIRI pourrait être administré en pratique courante chez les personnes âgées sous couvert d’une évaluation gériatrique et d’une approche multidisciplinaire.

Keywords: Bevacizumab; Cohort; Daily practice; Elderly patients; Liver surgical resection; Metastatic colorectal cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of population by age and sex
Fig. 2
Fig. 2
Kaplan Meier overall survival analysis for less than 70 years patients and for over 70 years
Fig. 3
Fig. 3
Kaplan Meier overall survival analysis according to metastases resection
Fig. 4
Fig. 4
Kaplan Meier progression free survival analysis for less than 70 years patients and for over 70 years
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–1475. doi: 10.1016/j.ejca.2012.02.057. - DOI - PubMed
    1. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705. doi: 10.1200/JCO.2009.27.4860. - DOI - PubMed
    1. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214. doi: 10.1200/JCO.2004.11.037. - DOI - PubMed
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691. - DOI - PubMed
    1. Pectasides D, Papaxoinis G, Kalogeras K, et al. XELIRI- Bevacizumab versus FOLFIRI-Bevacizumab as first line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology group phase III Trial with collateral biomarker analysis. BMC Cancer. 2012;12:271. doi: 10.1186/1471-2407-12-271. - DOI - PMC - PubMed

LinkOut - more resources